Topic: chief medical officer
Precision immunodiagnostic firm Navidea Biopharmaceuticals named Michael Rosol, Ph.D., to be its new chief medical officer, effective Dec. 17.
Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors.
Tocagen has named Lori Kunkel as its acting CMO after the departure of Asha Das, who is leaving because of “immediate personal matters.”
Ziopharm Oncology’s executive vice president of R&D, Francois Lebel, M.D., is moving to cancer drugmaker Spectrum Pharmaceuticals effective Nov. 5.
Former Merck clinical research leader Arthur Santora is coming out of retirement to serve as chief medical officer of Entera Bio.
Radius Health brought on Charles Morris to be CMO and oversee its expansion into oncology, with two breast cancer treatments in early-phase trials.
Sanofi VP Riccardo Perfetti has jumped to metabolic disease startup Applied Therapeutics to become its CMO as it moves into first-in-human trials.
Sensei Biotherapeutics named Ildiko Csiki as CMO. Csiki was previously VP of immuno-oncology clinical development at Inovio Pharmaceuticals.
Sanofi’s global head of diabetes late-stage development, Eckhard Leifke, will move to Omeros to be its CMO and VP of clinical development.
Beijing’s CANbridge Life Sciences, developing Western drug candidates in China and Asia, brought on Pfizer’s May Orfali to be chief medical officer.